Tumor ablation by gene-modified T cells in the absence of autoimmunity.
about
Chimeric Antigen Receptors Modified T-Cells for Cancer TherapyCellular immunotherapy for pediatric solid tumorsEvolution of animal models in cancer vaccine developmentT-cell receptor gene therapy--ready to go viral?Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyImmunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCell-based immunotherapy against gliomas: from bench to bedsideA role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Cancer vaccines inducing antibody production: more pros than cons.Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers.CAR T-cell therapy: toxicity and the relevance of preclinical models.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term.Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.Driving better and safer HER2-specific CARs for cancer therapy.Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Genetically enhanced T lymphocytes and the intensive care unit.
P2860
Q26773309-80A87D80-6195-4A84-9E36-6B1CA8E8C8C9Q27014912-05362140-26E2-44F7-9B96-948BBE7DB219Q28080739-E7DBD3EE-7BC6-438B-B7E1-D8F77F04C887Q28081611-A7794F84-5F9F-4A5D-9ACF-5CAB796C6537Q30403182-6B59F587-AA54-40D3-8729-0B76F458C910Q33587034-86CE457C-E85B-4263-9ACD-0D752E8C861CQ34550649-511D1D12-B080-4398-9394-7D1BCF23A028Q36470354-8E0C846E-A32C-4823-B54A-906134A2B33FQ36984482-107FE574-2DBD-4AB6-863B-9B19A2B8F39EQ37376346-DF41DCD8-008A-46ED-BFF2-DBCD08C20458Q37536195-EC380CB0-13AD-4C80-A07C-219197C2F9DAQ37932519-0100398B-14D6-4BC5-A8C9-6CEF1CF669A3Q38244698-09C83E16-F556-4440-BF0F-2383957A3108Q38525018-70CA6522-EB1E-40E8-978D-E114EB4AC8A8Q38525024-6BB4D1DE-1B82-444F-9115-A31020E54064Q38741113-5C520192-1375-45DC-A871-4B41A27B7A79Q39387987-64E263F5-E0C6-42BE-A808-78BFF38C0115Q39790928-EEA81A53-DB66-4049-8D80-C883288B6AA6Q41625041-0552C227-951A-4F43-9240-45DF92FFFB0CQ41835996-79B12352-F95E-4143-90E1-335226939EADQ42683483-9F9442D2-25B8-48D0-9946-CDAC7699AA1DQ50024580-30B682A5-49E7-4F01-A2B9-16FA1E8B2323Q50531950-BFE56CA9-F4CF-41FD-92A2-DC243B68A2A6Q55380614-C2216B7A-4DE6-4DE4-A93B-CA21E241DDF7
P2860
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@en
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@nl
type
label
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@en
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@nl
prefLabel
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@en
Tumor ablation by gene-modified T cells in the absence of autoimmunity.
@nl
P2093
P50
P1433
P1476
Tumor ablation by gene-modified T cells in the absence of autoimmunity
@en
P2093
Jennifer A Westwood
Jordane Malaterre
Leanne X J Wang
Maria Moeller
Wei-Zen Wei
P304
P356
10.1158/0008-5472.CAN-10-2884
P407
P577
2010-11-23T00:00:00Z